Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026 at 8:00 a.m. ET.
The fireside chat and Q&A will be webcast live on the company's investor relations site, with an archived replay available within 24 hours and accessible through March 25, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – DGX
On the day this news was published, DGX declined 0.83%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: LH up 0.68%, NTRA up 0.54%, while WAT and MTD are down and PKI is flat, suggesting today’s action in DGX is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Earnings and guidance | Positive | +7.4% | Strong 2025 results, raised 2026 guidance, and higher quarterly dividend. |
| Feb 10 | Dividend and buyback | Positive | +7.4% | Dividend raised 7.5% and $1B increase to share repurchase authorization. |
| Feb 2 | Product launch | Positive | -1.1% | Launch of ultrasensitive flow cytometry MRD blood test for myeloma. |
| Jan 21 | Corporate recognition | Positive | -2.3% | Named to Fortune’s 2026 World’s Most Admired Companies list, ranked #2 in category. |
| Jan 15 | Leadership transition | Neutral | +1.9% | CEO-elect announced for Sonora Quest with planned transition from long-time CEO. |
DGX has shown its strongest positive reactions to financial and capital-return announcements, while recognition or product-launch news has produced more muted or negative next-day moves.
Over recent months, DGX reported strong Q4 and full-year 2025 results with higher 2026 guidance and a 7.5% dividend increase, which coincided with a +7.37% move, underscoring sensitivity to financial and shareholder-return news. A novel myeloma MRD test launch and inclusion on Fortune’s “Most Admired Companies” list saw modest negative reactions. Leadership transition news at Sonora Quest produced a smaller positive move. Against this backdrop, the Leerink conference appearance represents a routine investor-relations event rather than a major new catalyst.
Regulatory & Risk Context
The company has an effective S-3ASR automatic shelf registration filed on 2025-06-20, allowing it to issue debt securities on a delayed or continuous basis under Rule 415, with specific terms set in future prospectus supplements. The shelf remains effective through 2028-06-20 and has 0 recorded usages to date.
Market Pulse Summary
This announcement centers on DGX’s participation in the Leerink 2026 Global Healthcare Conference, where the CFO will discuss strategy, performance, and market trends on March 11, 2026. It follows recent earnings and dividend news that drew a strong positive reaction of +7.37%, alongside more mixed responses to product and recognition updates. Investors may focus on any incremental commentary versus prior guidance, the tone on industry pricing and regulation, and how management frames capital allocation and balance-sheet flexibility.
AI-generated analysis. Not financial advice.
The Fireside Chat and Q&A session will be webcast live during the conference on the company's investor relations page, which can be accessed at ir.QuestDiagnostics.com. In addition, the archived webcast will be available within 24 hours after the conclusion of the live event and will remain available until March 25, 2026.
About Quest Diagnostics
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-leerink-2026-global-healthcare-conference-302697113.html
SOURCE Quest Diagnostics
FAQ
When will Quest Diagnostics (DGX) present at the Leerink 2026 Global Healthcare Conference?
How can investors watch the Quest Diagnostics (DGX) Leerink 2026 presentation live?
Will Quest Diagnostics (DGX) provide a replay of the Leerink 2026 presentation and for how long?
Who from Quest Diagnostics (DGX) will speak at the Leerink 2026 Global Healthcare Conference?
What topics will Quest Diagnostics (DGX) cover during the March 11, 2026 Leerink presentation?
Where can I find the archived webcast of Quest Diagnostics (DGX) after the Leerink 2026 event?
